Azam Moosavi | Biochemistry | Best Researcher Award

Dr. Azam Moosavi | Biochemistry | Best Researcher Award

R&D lab Manager/supervisor of innovation center of SCARM(Stem Cell and Regenerative Medicine) from Tabriz University of Medical Sciences, Iran

Dr. Azam Moosavi is a dedicated and innovative biochemist specializing in beta-cell regeneration for the treatment of Type 1 diabetes. With a strong academic foundation and a passion for interdisciplinary research, she integrates molecular biology, regenerative medicine, and clinical biochemistry in her scientific work. Over her academic and professional career, she has developed a notable track record in research, mentorship, and laboratory management. Her research aims to translate scientific findings into real-world applications, especially for chronic diseases like diabetes. She has contributed to several peer-reviewed publications, presented at major international conferences, and co-authored a book chapter on bioactive peptides. Currently serving as R&D and Cell Culture Lab Manager at the Innovation Center of Stem Cells and Regenerative Medicine at Tabriz University of Medical Sciences, Dr. Moosavi is also actively involved in mentoring young researchers. With additional expertise in teaching, clinical laboratory operations, and scientific writing, she brings a multifaceted approach to biomedical research. Her work demonstrates both academic rigor and practical impact, and she is highly regarded for her contributions to translational medicine, epigenetics, and molecular diagnostics. Dr. Moosavi continues to strive toward scientific excellence, combining curiosity with applied innovation in pursuit of better health solutions.

Professional Profile

Education

Dr. Azam Moosavi’s academic journey reflects her deep commitment to biomedical sciences and health research. She earned her Ph.D. in Biochemistry from the Institute of Biochemistry and Biophysics (IBB) at the University of Tehran, where her thesis focused on beta-cell regeneration in Type 1 diabetes through pharmaceutical induction. Her Ph.D. was marked by an impressive GPA (3.7/4) and resulted in multiple scientific presentations and publications. Prior to that, she completed a Master of Public Health (MPH) in Health Management and Reform at Tehran University of Medical Sciences, focusing on strategic risk management in health systems. She also holds an M.Sc. in Biochemistry from Tarbiat Moallem University in Tehran, where she investigated alpha thalassemia genetics, leading to multiple congress presentations. Dr. Moosavi began her academic training with a Bachelor of Science in Clinical Laboratory Sciences from Mashhad University of Medical Sciences, followed by an Associate degree in the same field from Tehran University of Medical Sciences. Her academic record is consistent, with GPA scores ranging from 3.3 to 3.9, showcasing a solid grasp of theory and practice. These multidisciplinary qualifications equip her with a robust foundation for both laboratory research and healthcare innovation.

Professional Experience

Dr. Moosavi brings over two decades of experience spanning research, laboratory management, and academic instruction. Since March 2023, she has served as R&D and Cell Culture Lab Manager at the Innovation Center of Stem Cells and Regenerative Medicine (SCARM), Tabriz University of Medical Sciences. Here, she supervises experimental design, oversees lab operations, mentors postgraduates, and contributes to cutting-edge regenerative research. Prior to this role, Dr. Moosavi spent ten years teaching biochemistry laboratory courses to medical, dental, and pharmacy students at Alborz University of Medical Sciences. Her instruction emphasized clinical applications and hands-on skills, significantly enhancing student competency in diagnostics. Between 2005 and 2013, she managed clinical laboratories in various health centers and at Kasra Hospital in Karaj, where she was responsible for quality control, team supervision, and staff training across hematology, microbiology, and biochemistry divisions. In addition to her formal roles, she has led workshops in quality control and hematology testing, implemented risk management strategies, and participated in numerous clinical and academic projects. Her professional journey is characterized by leadership in education, hands-on expertise in diagnostics, and a drive to integrate innovative research with public health practice.

Research Interests

Dr. Moosavi’s research interests are centered on the intersection of molecular biology, regenerative medicine, and clinical diagnostics. Her primary focus is on beta-cell regeneration as a therapeutic strategy for Type 1 diabetes—a condition she explores through pharmaceutical, genetic, and immunological lenses. She is particularly interested in cell-based models, gene regulatory networks, and high-tech therapeutic interventions aimed at reversing or halting disease progression. Her passion for stem cell biology and regenerative therapies is reflected in her involvement with mesenchymal stem cell research and the use of exosomes in clinical settings. Beyond diabetes, she has contributed to projects involving autoimmune disorders, fertility research, cancer diagnostics, and infectious diseases like COVID-19. Her work also explores epigenetic regulation, as evidenced by a highly cited publication on the role of epigenetics in human diseases. In addition, Dr. Moosavi is eager to integrate new technologies into her research, including artificial intelligence (AI), next-generation sequencing (NGS), and gene editing techniques. This interdisciplinary approach allows her to not only study disease mechanisms at the molecular level but also develop actionable, personalized treatment strategies. She continuously expands her research portfolio with a strong commitment to innovation and translational impact.

Research Skills

Dr. Moosavi has cultivated a wide array of research skills that span molecular techniques, computational analysis, and laboratory management. She is proficient in essential molecular biology methods including PCR, ELISA, Western blotting, and routine clinical laboratory testing. Her expertise also includes cell culture, particularly in managing regenerative medicine labs, as well as conducting experiments on the apoptotic effects of compounds and stem cell secretome applications. In addition to wet-lab skills, she is experienced in data analysis and literature management using tools like GraphPad Prism, RevMan5, and EndNote. Her training in Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) principles supports her ability to implement and monitor high-quality standards in laboratory settings. Moreover, she is well-versed in risk management using Failure Mode and Effects Analysis (FMEA), which she has applied to improve safety and operational efficiency in academic laboratories. With intermediate proficiency in English and basic command of German and Azerbaijani, she is also equipped for international collaboration. Altogether, her technical and analytical competencies allow her to conduct research that is both scientifically rigorous and aligned with current regulatory standards.

Awards and Honors

Dr. Azam Moosavi has received several notable recognitions throughout her academic and professional journey. She secured third place nationally in the Ph.D. entrance exam for biochemistry at the University of Tehran, reflecting her strong academic standing. Her contributions to the field of molecular biology and regenerative medicine have been acknowledged at prestigious conferences, including the Best Poster Award at the 17th National and 8th International Congress of Biochemistry and Molecular Biology in 2023. Additionally, she was selected as the first presenter in the Young Researchers’ Section at the 15th International & 21st National Congress on Quality Improvement in Clinical Laboratories in 2024. Beyond academic accolades, Dr. Moosavi holds a patent related to lung cancer antibody production using nanopharmaceutical technology, underscoring her innovation in translational research. She also earned third position in the National Industrial Innovation Competition, further recognizing her role in applied scientific development. These honors validate her dedication to excellence, whether in academic research, laboratory innovation, or public health impact. Collectively, these awards demonstrate Dr. Moosavi’s significant contributions to biomedical science and affirm her as a rising leader in the fields of biochemistry and regenerative medicine.

Conclusion

Dr. Azam Moosavi emerges as a well-qualified candidate for the Best Researcher Award, with extensive contributions to biochemistry, regenerative medicine, and clinical laboratory science. Her academic credentials, professional experience, and interdisciplinary research projects collectively demonstrate excellence in both theoretical and applied science. Through her focus on beta-cell regeneration for Type 1 diabetes, Dr. Moosavi has tackled a major public health challenge using innovative and translational approaches. Her record includes numerous peer-reviewed publications, international presentations, patents, and awards, positioning her as a leader in her field. She has also played a key role in education and mentorship, nurturing the next generation of biomedical researchers. With solid research skills, an expanding network of collaborations, and a commitment to continuous learning, Dr. Moosavi has built a career marked by impact, growth, and forward-thinking science. Moving forward, she is poised to make even greater contributions through high-impact research, interdisciplinary teamwork, and international engagement. Her profile exemplifies the qualities that the Best Researcher Award seeks to honor: intellectual rigor, practical innovation, and a drive to improve human health through science.

Publications Top Notes

  1. Beta Cell Regeneration upon Magainin and Growth Hormone Treatment as a Possible Alternative to Insulin Therapy
    Journal: FEBS Open Bio, 2023
    Authors: Azam Moosavi, Razieh Yazdanparast

  2. Human Herpesvirus 6 Infection and Risk of Chronic Fatigue Syndrome: A Systematic Review and Meta-Analysis
    Journal: Intervirology, 2022
    Author: Azam Moosavi

  3. A Systematic Review and Meta-Analysis on the Epidemiology, Causal Agents and Demographic Characteristics of Onychomycosis in Iran
    Journal: Medical Mycology, 2019
    Author: Azam Moosavi

  4. Environmental Exposure to Endotoxin and Its Health Outcomes: A Systematic Review
    Journal: Ecotoxicology and Environmental Safety, 2019
    Author: Azam Moosavi

  5. The Frequency of Fungi Isolated from the Skin and Hair of Asymptomatic Cats in Rural Area of Meshkin-shahr, Iran
    Journal: Journal de Mycologie Médicale, 2019
    Authors: A. Moosavi, R.D. Ghazvini, K. Ahmadikia, S.J. Hashemi, M. Geramishoar, M. Mohebali, M.S. Yekaninejad, H. Bakhshi, M. Khodabakhsh

  6. The Frequency and Importance of Common α-globin Gene Deletions among β-thalassemia Carriers in an Iranian Population
    Journal: Avicenna Journal of Medical Biotechnology, 2017
    Authors: A. Moosavi, A.M. Ardekani

  7. Role of Epigenetics in Biology and Human Diseases
    Journal: Iranian Biomedical Journal, 2016
    Author: Azam Moosavi

  8. Bioactive Peptides
    Publisher: CRC Press, 2021
    Author: Azam Moosavi

  9. Effect of Vitamin B6 Supplementation on Biochemical Values in Type 2 Diabetes Mellitus
    Conference: Congress on Quality Improvement in Clinical Laboratories, 2015
    Author: Azam Moosavi

 

Mohammad Sadegh Hashemzadeh | Biochemistry |Best Researcher Award

Assist Prof Dr. Mohammad Sadegh Hashemzadeh | Biochemistry |Best Researcher Award

AssistProfessor at Nanobiotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

Dr. Mohammad Sadegh Hashemzadeh is an accomplished Assistant Professor at Baqiyatallah University of Medical Sciences, specializing in Medical and Nano Biotechnology. He holds a Ph.D. in Nano Biotechnology, with a focus on recombinant protein production for therapeutic applications, including cell therapy for rheumatoid arthritis. Dr. Hashemzadeh has received numerous accolades, including top ranks in his B.Sc., M.Sc., and Ph.D. studies, and has published extensively in reputable journals on topics such as nanotechnology, viral protein production, and cancer treatment. His research expertise spans molecular genetics, genetic engineering, and the development of novel diagnostic methods for biological threats. Dr. Hashemzadeh’s contributions to the field are recognized internationally, making him a prominent figure in biotechnology research, particularly in Iran. His work bridges the gap between cutting-edge biotechnology and practical medical applications, reflecting his dedication to advancing health sciences.

Profile

Education

Dr. Mohammad Sadegh Hashemzadeh boasts an exemplary educational background in biotechnology and medical sciences. He began his academic journey with a Bachelor of Science (B.Sc.) degree, graduating with top honors and consistently ranking first among his peers. Driven by his passion for advanced research, Dr. Hashemzadeh pursued a Master of Science (M.Sc.) degree, where he continued to excel academically and was recognized for his outstanding performance. He then attained his Ph.D. in Nano Biotechnology from Baqiyatallah University of Medical Sciences, a prestigious institution in Iran, where he focused on recombinant protein expression and the application of nanotechnology in medical diagnostics. Following his doctoral studies, Dr. Hashemzadeh undertook postdoctoral research at the Pasteur Institute of Iran, specializing in innovative cell therapy techniques for rheumatoid arthritis. Throughout his education, he has received numerous accolades, including the first prize at the 15th International Congress of Microbiology, underscoring his dedication and excellence in the field. His comprehensive education has provided him with a solid foundation in molecular genetics, genetic engineering, and cutting-edge biotechnological methodologies.

Professional Experience

Dr. Mohammad Sadegh Hashemzadeh is an accomplished Assistant Professor at Baqiyatallah University of Medical Sciences, Tehran, Iran, with a strong background in Medical and Nano Biotechnology. His expertise spans molecular genetics, genetic engineering, and cell culture, focusing on producing recombinant proteins for therapeutic applications. Dr. Hashemzadeh’s research interests include cell therapy for rheumatoid arthritis, recombinant protein production, and viral vector engineering. He has completed a Post-Doc in cell therapy of inflammatory diseases and has been involved in various research projects, including the construction of recombinant viruses and the development of viral-like particles (VLPs) for potential therapeutic use. In addition to his research contributions, Dr. Hashemzadeh is an experienced educator, having taught courses in genetics, immunology, and nanotechnology at both undergraduate and postgraduate levels. His professional achievements are further underscored by his numerous publications in high-impact journals and his recognition through several awards and honors.

Research Interest

Dr. Mohammad Sadegh Hashemzadeh’s research interests primarily focus on the intersection of medical biotechnology and nano-biotechnology. His work spans the development of advanced therapeutic applications, particularly in molecular genetics, genetic engineering, and cell therapy for inflammatory diseases like rheumatoid arthritis. He is deeply engaged in the production of recombinant proteins, utilizing cell culture techniques to develop viral vectors and virus-like particles (VLPs) for potential cancer treatments and vaccine development. His research also includes exploring the role of peptide nucleic acids (PNAs) in detecting and treating diseases caused by biological threat agents. Additionally, Dr. Hashemzadeh investigates the application of oncolytic viruses in cancer therapy and the development of novel diagnostic methods using nanotechnology. His work is aimed at translating cutting-edge biotechnological advancements into practical solutions for complex medical challenges, contributing to the fields of virology, immunology, and therapeutic protein production.

Research Skills

Dr. Mohammad Sadegh Hashemzadeh possesses a diverse and advanced skill set in the field of biotechnology and nanotechnology. His expertise encompasses molecular genetics, genetic engineering, and cell culture, with a focus on producing recombinant proteins for therapeutic applications. His research is distinguished by his proficiency in the development and application of viral vectors and protein-based vaccines, particularly in the context of cell therapy and vaccine production. Dr. Hashemzadeh has extensive experience in the expression, solubilization, and purification of recombinant proteins, utilizing techniques such as real-time PCR and nanotechnology for diagnostic and therapeutic purposes. His work involves the synthesis and characterization of nanomaterials and viral-like particles (VLPs), contributing to advancements in diagnostic methods and biological threat detection. His skills are supported by a robust publication record in international journals, reflecting his significant contributions to the fields of molecular biotechnology and medical research.

Award and Recognition

Dr. Mohammad Sadegh Hashemzadeh has garnered notable recognition for his exceptional contributions to the fields of biotechnology and nanotechnology. His academic journey is marked by distinguished achievements, including being first-ranked among his peers during his MSc and PhD studies, and receiving accolades such as the First Prize at the 15th International Congress of Microbiology in 2014. His innovative research has been published in prestigious journals, underscoring his influence in the scientific community. Dr. Hashemzadeh’s work on the development of recombinant proteins and viral protein vaccines, as well as his significant contributions to the understanding of biological threat agents through nanotechnology, has earned him commendation. His dedication to advancing medical biotechnology and his role in pioneering research in cell therapy and genetic engineering reflect his outstanding contributions and make him a deserving candidate for further recognition and awards.

Conclusion

Dr. Mohammad Sadegh Hashemzadeh is a highly qualified candidate for the Research for Best Researcher Award, with a solid academic foundation, a track record of excellence in research, and contributions to medical biotechnology and nanotechnology. His continuous pursuit of innovative research and dedication to teaching underscore his suitability for this award. However, to further strengthen his candidacy, increased focus on collaborative research, securing research funding, and enhancing the practical application of his work could be beneficial.

Publications Top Notes

  1. Zinc Oxide Nanoparticles and Cancer Chemotherapy: Helpful Tools for Enhancing Chemo-sensitivity and Reducing Side Effects?
    • Authors: Vaghari-Tabari, M., Jafari-Gharabaghlou, D., Mohammadi, M., Hashemzadeh, M.S.
    • Journal: Biological Trace Element Research
    • Year: 2024
    • Volume and Issue: 202(5), pp. 1878–1900
    • Citations: 3
  2. Therapeutic Effects of IL-1RA, M2 Cells, and Their Synergistic Impact on a Mouse Model of Rheumatoid Arthritis
    • Authors: Hashemzadeh, M.S., Ghaleh, H.E.G., Mohammadi, M., Rezaei, E., Alishiri, G.
    • Journal: Advanced Pharmaceutical Bulletin
    • Year: 2024
    • Volume and Issue: 14(2), pp. 483–495
    • Citations: 0
  3. Correction: Biosynthesis of a VLP-type nanocarrier specific to cancer cells using the BEVS expression system for targeted drug delivery (Journal of Genetic Engineering and Biotechnology, (2023), 21, 1, (20), 10.1186/s43141-023-00479-9)
    • Authors: Hashemzadeh, M.S., Gharari, N.
    • Journal: Journal of Genetic Engineering and Biotechnology
    • Year: 2023
    • Volume and Issue: 21(1), 40
    • Citations: 1
  4. Biosynthesis of a VLP-type nanocarrier specific to cancer cells using the BEVS expression system for targeted drug delivery
    • Authors: Hashemzadeh, M.S., Gharari, N.
    • Journal: Journal of Genetic Engineering and Biotechnology
    • Year: 2023
    • Volume and Issue: 21(1), 20
    • Citations: 3
  5. Utilization of Freeze-Thawing Method for High-level Expression of Functional Human Epidermal Growth Factor (hEGF)
    • Authors: Mohammadi, M., Ghanbari, S., Emamgholi, A., Hashemzadeh, M.S.
    • Journal: International Journal of Peptide Research and Therapeutics
    • Year: 2023
    • Volume and Issue: 29(3), 38
    • Citations: 1
  6. Utilization of SUMO Tag and Freeze-thawing Method for a High-level Expression and Solubilization of Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) Protein in E. coli
    • Authors: Mohammadi, M., Taheri, R.A., Bemani, P., Farnoosh, G., Amini, R.
    • Journal: Protein and Peptide Letters
    • Year: 2022
    • Volume and Issue: 29(7), pp. 605–610
    • Citations: 4
  7. Evaluation of the acute and 28-day sub-acute intravenous toxicity of α-l-guluronic acid (ALG; G2013) in mice
    • Authors: Mahdian-Shakib, A., Hashemzadeh, M.S., Anissian, A., Oraei, M., Mirshafiey, A.
    • Journal: Drug and Chemical Toxicology
    • Year: 2022
    • Volume and Issue: 45(1), pp. 151–160
    • Citations: 6
  8. The role of bacterial superantigens in the immune response: From biology to cancer treatment
    • Authors: Hashemzadeh, M.S., Tapeh, B.E.G., Mirhosseini, S.A.
    • Journal: Current Cancer Therapy Reviews
    • Year: 2021
    • Volume and Issue: 17(1), pp. 21–34
    • Citations: 1
  9. Expression, solubilization, refolding and final purification of recombinant proteins as expressed in the form of “classical inclusion bodies” in e. coli
    • Authors: Hashemzadeh, M.S., Mohammadi, M., Ghaleh, H.E.G., Choopani, A., Panda, A.K.
    • Journal: Protein and Peptide Letters
    • Year: 2021
    • Volume and Issue: 28(2), pp. 2–10
    • Citations: 16
  10. Detection of West Nile virus by real-time PCR in crows in northern provinces of Iran
    • Authors: Sharti, M., Amouakbari, M.J., Pourjabari, K., Omidifar, A., Dorostkar, R.
    • Journal: Journal of Vector Borne Diseases
    • Year: 2020
    • Volume and Issue: 57(1), pp. 37–39
    • Citations: 2